Standard BioTools Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Standard BioTools Inc. (LAB) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $561.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-16
- Standard BioTools Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $561.00K, a 79.08% decline from fiscal 2024.
- Standard BioTools Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $2.68M.
- Standard BioTools Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Standard BioTools Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2021 was $325.00K, a 26.30% decline from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $561.00K 10-K · filed 2026-03-16 |
| 2024-12-31 | $2.68M 10-K · filed 2026-03-16 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 |
| 2021-12-31 | $325.00K 10-K · filed 2023-03-14 |
| 2020-12-31 | $441.00K 10-K · filed 2022-03-08 |
| 2019-12-31 | $354.00K 10-K · filed 2022-03-08 |
| 2018-12-31 | $255.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $61.00K 10-K · filed 2020-02-27 |
| 2016-12-31 | $1.67M 10-K · filed 2019-03-18 |
| 2015-12-31 | $1.05M 10-K · filed 2018-03-08 |
| 2014-12-31 | $832.00K 10-K · filed 2017-03-03 |
| 2013-12-31 | $1.04M 10-K · filed 2016-02-29 |
| 2012-12-31 | $903.00K 10-K · filed 2015-02-26 |
| 2011-12-31 | $652.00K 10-K · filed 2014-03-12 |
| 2010-12-31 | $873.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |